XML 72 R35.htm IDEA: XBRL DOCUMENT v3.21.2

Segments (Tables)

6 Months Ended

12 Months Ended

Jul. 03, 2021

Dec. 31, 2020

Schedule Of Reconciliation Of Operating Profit (Loss) From Segments To Consolidated

The following table presents segment adjusted EBITDA reconciled to income before income taxes:

		Three Months Ended								Six Months Ended
		July 3, 2021				June 27, 2020				July 3, 2021				June 27, 2020
Segment adjusted EBITDA
U.S.		$	17,149			$	7,439			$	27,147			$	21,151
International			2,738				(497	)			3,810				37
Depreciation and amortization			(7,479	)			(7,248	)			(14,663	)			(14,513	)
Interest (expense) income			(1,681	)			(2,834	)			1,195				(5,215	)
Equity compensation			(5,853	)			(255	)			16,559				6,771
COVID-19 benefits, net			—				1,101				—				1,101
Succession and transition charges			(187	)			(3,801	)			(344	)			(4,574	)
Foreign currency impact			12				46				64				(40	)
Acquisition and integration costs			(1,833	)			—				(5,029	)			—
Inventory step-up costs			(2,106	)			—				(2,106	)
Equity loss in unconsolidated investments			(432	)			—				(901	)			—
Change in fair value of contingent consideration			(641	)			—				(641	)			—
Impairments related to variable interest entity			(7,043	)			—				(7,043	)			—
Other non-recurring costs			(1,710	)			(41	)			(2,659	)			(283	)
(Loss) income before income taxes		$	(9,066	)		$	(6,090	)		$	15,389			$	4,435

Bio Ventus LLC

Schedule Of Reconciliation Of Operating Profit (Loss) From Segments To Consolidated

The following table presents segment adjusted EBITDA reconciled to income from continuing operations before income taxes for the years ended December 31 as follows:

		2020				2019				2018
Segment adjusted EBITDA from continuing operations
U.S.		$	69,252			$	71,673			$	67,480
International			3,191				7,515				4,691
Depreciation and amortization			(28,643	)			(30,316	)			(29,238	)
Interest expense			(9,751	)			(21,579	)			(19,171	)
Equity compensation			(10,103	)			(10,844	)			(14,325	)
COVID-19 benefits, net			4,123				—				—
Succession and transition charges			(5,609	)			—				—
Restructuring costs			(563	)			(575	)			(1,373	)
Foreign currency impact			117				(8	)			(234	)
Equity loss in unconsolidated investments			(467	)			—				—
Other non-recurring costs			(5,633	)			(6,177	)			(1,723	)
Income from continuing operations before income taxes		$	15,914			$	9,689			$	6,107

X

- Definition

Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599

+ Details

Name:	us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Details

Name:	dei_LegalEntityAxis=bvs_BioVentusLlcMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: